MTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats

Journal of Parkinson's Disease

Volumn 3, Issue 1, 2013, Pages 13-17

  Decressac, Mickael ^a   Björklund, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

dyskinesia; mTOR inhibition; Parkinson's disease

Indexed keywords

LEVODOPA; MAMMALIAN TARGET OF RAPAMYCIN; TEMSIROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; DYSKINESIA; ENZYME INHIBITION; FEMALE; IMMUNOHISTOCHEMISTRY; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STRIATE CORTEX; SYSTEMIC THERAPY;

ANIMALS; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; PARKINSON DISEASE; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84880243271     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-120155     Document Type: Article

References (14)

1. Ahlskog JE, & Muenter MD (2001) Frequency of levodoparelated dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord, 16, 448-458.
2. Gerfen CR, Miyachi S, Paletzki R, & Brown P (2002) D1 dopamine receptor supersensitivity in the dopaminedepleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci, 22, 5042-5054.
3. Santini E, Heiman M, Greengard P, Valjent E, & Fisone G (2009) Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Sci Signal, 2, ra36.
4. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, HerveD, Greengard P,&FisoneG(2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci, 27, 6995-7005.
5. Subramaniam S, Napolitano F, Mealer RG, Kim S, Errico F, BarrowR, Shahani N,Tyagi R, Snyder SH,&UsielloA(2012) Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia. Nat Neurosci, 15, 191-193.
6. Benjamin D, Colombi M, Moroni C, & Hall MN (2011) Rapamycin passes the torch: A new generation of mTOR inhibitors. Nat Rev Drug Discov, 10, 868-880.
7. Santini E, Valjent E, & Fisone G (2010) mTORC1 signaling in Parkinson's disease and L-DOPA-induced dyskinesia: A sensitized matter. Cell Cycle, 9, 2713-2718.
8. Decressac M, Mattsson B,&Bj̈orklundA(2012) Comparison of the behavioural and histological characteristics of the 6-OHDAand alpha-synuclein rat models of Parkinson's disease. Exp Neurol, 235, 306-315.
9. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O'Kane CJ, & Rubinsztein DC (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet, 36, 585-595.
10. Lee CS, Cenci MA, Schulzer M, & Bj̈orklund A (2000) Embryonic ventral mesencephalic grafts improve levodopainduced dyskinesia in a rat model of Parkinson's disease. Brain, 123(Pt 7), 1365-1379.
11. Lundblad M, Andersson M,Winkler C, Kirik D,Wierup N,& Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci, 15, 120-132.
12. Knight ZA,TanK, BirsoyK, Schmidt S, Garrison JL,Wysocki RW, Emiliano A, Ekstrand ML, & Friedman JM (2012) Molecular profiling of activated neurons by phosphorylated ribosome capture. Cell, 151, 1126-1137.
13. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, & Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med, 356, 2271-2281.
14. Richard DJ, Verheijen JC, & Zask A (2010) Recent advances in the development of selective, ATP-competitive inhibitors of mTOR. Curr Opin Drug Discov Devel, 13, 428-440.